Option Therapeutics Inc.

We are a clinical-stage company developing innovative drug therapies to treat debilitating and life-threatening liver disease through our investigational drug candidate BIV201 (continuous infusion terlipressin). BIV201 has been granted both Food and Drug Administration (“FDA”) Fast Track designation status and FDA Orphan Drug Status, which designations provide certain advantages in the review process, but do not guarantee a faster development process, regulatory review or approval as compared to the conventional FDA review and approval process. BIV201 is being evaluated as a treatment option for patients suffering from ascites and other life-threatening complications of advanced liver cirrhosis caused by metabolic dysfunction-associated steatohepatitis (“MASLD”), hepatitis, and alcoholism. BIV201 is designed to be administered as a patented liquid formulation of terlipressin with patents issued, to date, in the U.S., Australia, China, Japan, Chile, and India, and with seven pending patent applications in the U.S. and other jurisdictions. Also, we own U.S. Patent No. 11,364,277, and European Patent No. EP3347032, which are directed to a method of treating ascites with BIV201, and we…

S-1/A · 2026-03-16 · 0001520138-26-000074

Company description from the cited filing.